probenecid has been researched along with Cystic Fibrosis in 9 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In both healthy subjects and patients with cystic fibrosis, compared with dicloxacillin alone, coadministration with probenecid produced a significantly lower renal clearance of dicloxacillin, whereas coadministration with cyclosporine resulted in no significant change; renal clearance was not significantly different between the two study groups." | 9.13 | Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. ( Beringer, PM; Burckart, GJ; Gill, M; Hidayat, L; Kriengkauykiat, J; Liu, S; Louie, S; Rao, PA; Shapiro, B; Synold, T; Zhang, X, 2008) |
| "Probenecid pharmacokinetics were studied in 5 cystic fibrosis (CF) subjects and 5 control subjects at oral dosages of 5, 15, and 30 mg/kg." | 7.68 | Probenecid pharmacokinetics in cystic fibrosis. ( de Groot, R; Ramsey, B; Smith, A; Weber, A; Williams-Warren, J, 1991) |
| " Eight cystic fibrosis patients and 8 healthy volunteers were recruited into a crossover pharmacokinetic study in which participants received 180 mg fexofenadine with or without 1 g probenecid twice a day." | 6.73 | Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. ( Beringer, PM; Burckart, GJ; Hidayat, L; Liu, S; Louie, S; Rao, AP; Shapiro, B, 2008) |
| " In both healthy subjects and patients with cystic fibrosis, compared with dicloxacillin alone, coadministration with probenecid produced a significantly lower renal clearance of dicloxacillin, whereas coadministration with cyclosporine resulted in no significant change; renal clearance was not significantly different between the two study groups." | 5.13 | Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. ( Beringer, PM; Burckart, GJ; Gill, M; Hidayat, L; Kriengkauykiat, J; Liu, S; Louie, S; Rao, PA; Shapiro, B; Synold, T; Zhang, X, 2008) |
| "Probenecid pharmacokinetics were studied in 5 cystic fibrosis (CF) subjects and 5 control subjects at oral dosages of 5, 15, and 30 mg/kg." | 3.68 | Probenecid pharmacokinetics in cystic fibrosis. ( de Groot, R; Ramsey, B; Smith, A; Weber, A; Williams-Warren, J, 1991) |
| " Eight cystic fibrosis patients and 8 healthy volunteers were recruited into a crossover pharmacokinetic study in which participants received 180 mg fexofenadine with or without 1 g probenecid twice a day." | 2.73 | Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. ( Beringer, PM; Burckart, GJ; Hidayat, L; Liu, S; Louie, S; Rao, AP; Shapiro, B, 2008) |
| "Probenecid pretreatment in six patients was without effect on T 1/2 beta and Cl beta." | 1.27 | Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ( Blumer, JL; Kercsmar, CM; Murdell, D; Myers, CM; Reed, MD; Stern, RC, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Liu, S | 2 |
| Beringer, PM | 2 |
| Hidayat, L | 2 |
| Rao, AP | 1 |
| Louie, S | 2 |
| Burckart, GJ | 2 |
| Shapiro, B | 2 |
| Kriengkauykiat, J | 1 |
| Zhang, X | 1 |
| Synold, T | 1 |
| Rao, PA | 1 |
| Gill, M | 1 |
| Kercsmar, CM | 1 |
| Stern, RC | 2 |
| Reed, MD | 2 |
| Myers, CM | 1 |
| Murdell, D | 1 |
| Blumer, JL | 2 |
| Szaff, M | 1 |
| Høiby, N | 1 |
| Corvaia, L | 1 |
| Li, SC | 1 |
| Ioannides-Demos, LL | 1 |
| Bowes, G | 1 |
| Spicer, WJ | 1 |
| Spelman, DW | 1 |
| Tong, N | 1 |
| McLean, AJ | 1 |
| Weber, A | 1 |
| de Groot, R | 1 |
| Ramsey, B | 1 |
| Williams-Warren, J | 1 |
| Smith, A | 1 |
| Klinger, JD | 1 |
| Yamashita, TS | 1 |
| Meyers, CM | 1 |
| Blum, A | 1 |
| Huang, NN | 1 |
| Hiller, EJ | 1 |
| Macri, CM | 1 |
| Capitanio, M | 1 |
| Cundy, KR | 1 |
2 trials available for probenecid and Cystic Fibrosis
| Article | Year |
|---|---|
Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2008 |
Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Contrast Medi | 2008 |
7 other studies available for probenecid and Cystic Fibrosis
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.
Topics: Adolescent; Adult; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Female; Humans; Kinetics; Ma | 1983 |
Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Dicloxacillin; F | 1982 |
A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis.
Topics: Adolescent; Adult; Cystic Fibrosis; Drug Interactions; Female; Humans; Male; Probenecid; Prospective | 1992 |
Probenecid pharmacokinetics in cystic fibrosis.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Cystic Fibrosis; Female; Half-Lif | 1991 |
Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas.
Topics: Adolescent; Adult; Ceftazidime; Child; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; | 1985 |
Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation.
Topics: Aerosols; Anti-Bacterial Agents; Aspartate Aminotransferases; Child; Cystic Fibrosis; Escherichia; H | 1971 |